ESA IV administration, by DOPPS country and cross-section

  N Ptnts Total N Wgtd %
DOPPS Country DOPPS Cross-section 173 431 40.2%
AusNZ D2(2002)
D3(2006) 411 458 88.8%
D3(2007) 367 422 88.3%
D4(2010) 194 243 81.5%
D4(2011) 250 310 81.0%
Belgium D2(2002) 396 500 77.1%
D3(2006) 464 468 99.3%
D3(2007) 365 373 97.9%
D4(2010) 415 417 99.5%
D4(2011) 379 395 96.5%
Canada D2(2002) 187 534 39.5%
D3(2006) 444 505 90.9%
D3(2007) 355 415 90.1%
D4(2010) 256 294 86.8%
D4(2011) 348 400 88.6%
France D2(2002) 203 423 54.5%
D3(2006) 426 486 88.8%
D3(2007) 441 483 90.8%
D4(2010) 282 307 91.4%
D4(2011) 350 378 92.6%
Germany D2(2002) 438 494 85.8%
D3(2006) 501 511 98.4%
D3(2007) 552 560 98.7%
D4(2010) 489 502 97.1%
D4(2011) 495 523 94.1%
Italy D2(2002) 150 497 30.9%
D3(2006) 402 443 91.6%
D3(2007) 411 454 91.1%
D4(2010) 410 446 91.8%
D4(2011) 428 469 91.9%
Japan D2(2002) 1,469 1,472 99.8%
D3(2006) 1,501 1,504 99.8%
D3(2007) 1,532 1,535 99.8%
D4(2010) 1,266 1,268 99.8%
D4(2011) 1,368 1,368 100.0%
Spain D2(2002) 282 556 53.5%
D3(2006) 593 601 98.7%
D3(2007) 489 497 97.9%
D4(2010) 523 532 98.3%
D4(2011) 491 496 98.6%
Sweden D2(2002) 250 510 44.4%
D3(2006) 355 501 68.1%
D3(2007) 359 467 77.9%
D4(2010) 248 375 67.4%
D4(2011) 270 407 67.3%
UK D2(2002) 120 510 19.4%
D3(2006) 227 392 55.0%
D3(2007) 208 312 56.5%
D4(2010) 197 311 60.6%
D4(2011) 267 372 67.8%
US D2(2002) 1,820 2,013 90.3%
D3(2006) 1,553 1,620 95.7%
D3(2007) 1,148 1,197 96.3%
D4(2010) 2,733 2,786 99.0%
D4(2011) 2,974 3,048 97.3%

Among patients prescribed any ESA

Please see additional methodological information in the Data Sources and Methods section.